# Study of LM-299 in Subjects Advanced Malignant Tumors

Source: https://onco.cc/trials/nct06650566/  
OnCo record `nct06650566` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of LM-299 in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.

## Summary

Study of LM-299 in Subjects Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT06650566 by LaNova Medicines Limited, with 108 participants planned, started 2024-10-09 and due to reach its primary completion in 2026-12. Interventions recorded: LM-299.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06650566
- Phase: 1/2
- Setting: A Phase I/II, Open-label, Dose Escalation and Dose Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of LM-299 Injection as Monotherapy or in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- Sponsor: LaNova Medicines Limited
- Enrolled: 108

## Sources

- ClinicalTrials.gov NCT06650566: https://clinicaltrials.gov/study/NCT06650566

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [LaNova Medicines](https://onco.cc/companies/lanova-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct06650566.json